Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia

被引：4
|
作者：
Trang, M. [1 ]
Hammel, J. P. [1 ]
Lakota, E. A. [1 ,3 ]
Safir, M. C. [1 ]
Bhavnani, S. M. [1 ]
Friedrich, L. [2 ,4 ]
Steenbergen, J. N. [2 ,5 ]
McGovern, P. C. [2 ,6 ]
Tzanis, E. [2 ,7 ]
Rubino, C. M. [1 ]
机构：
[1] Inst Clin Pharmacodynam Inc, Schenectady, NY 12305 USA
[2] Paratek Pharmaceut Inc, King Of Prussia, PA USA
[3] Vertex Pharmaceut Inc, Boston, MA USA
[4] AN2 Therapeut, Cambridge, MA USA
[5] Sci & Med Affairs Consulting LLC, Philadelphia, PA USA
[6] Venatorx Pharmaceut Inc, Malvern, PA USA
[7] Neurapt Therapeut, Philadelphia, PA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 01期
关键词：
omadacycline; pharmacokinetics; community-acquired bacterial pneumonia;
D O I：
10.1128/aac.02201-21
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Age is not a risk factor for mortality in severe community-acquired pneumonia
    Poulose, V
    Foo, D
    Tan, CH
    CHEST, 2003, 124 (04) : 188S - 188S
  • [42] RISK FACTORS FOR MORTALITY IN COMMUNITY-ACQUIRED BACTEREMIC PNEUMOCOCCAL PNEUMONIA
    Boronat, P.
    Cano, S.
    Anglada, M.
    Fernando, A.
    Almirall, J.
    Mesalles, E.
    Gimenez, M.
    Sauca, G.
    Modol, J. M.
    Moreno, J. M.
    Klamburg, J.
    INTENSIVE CARE MEDICINE, 2009, 35 : 89 - 89
  • [43] Severe community-acquired pneumonia: analysis of mortality risk factors
    Pereira, J
    Paiva, J
    Aguiar, L
    Barbosa, S
    Gomes, J
    Honrado, T
    Maia, I
    Massada, S
    Rios, M
    Sousa Dias, C
    Mota, A
    INTENSIVE CARE MEDICINE, 2002, 28 : S56 - S56
  • [44] Community-acquired pneumonia in inpatients:: mortality, comorbidity and risk classes
    Lacasta, JMRD
    Fernández, MG
    Gil, JC
    REVISTA CLINICA ESPANOLA, 2003, 203 (02): : 64 - 67
  • [45] The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
    Cilloniz, Catia
    Torres, Antoni
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (09) : 569 - 576
  • [46] Community-acquired pneumonia in older patients: Does age influence systemic cytokine levels in community-acquired pneumonia?
    Kelly, Emer
    MacRedmond, Ruth E.
    Cullen, Garret
    Greene, Catherine M.
    McElvaney, Noel G.
    O'Neill, Shane J.
    RESPIROLOGY, 2009, 14 (02) : 210 - 216
  • [47] Population Pharmacokinetics of Ceftaroline in Patients With Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
    Van Wart, Scott A.
    Forrest, Alan
    Khariton, Tatiana
    Rubino, Christopher M.
    Bhavnani, Sujata M.
    Reynolds, Daniel K.
    Riccobene, Todd
    Ambrose, Paul G.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (11): : 1155 - 1167
  • [48] Testing for coccidioidomycosis among patients with community-acquired pneumonia
    Chang, Douglas C.
    Anderson, Shoana
    Wannemuehler, Kathleen
    Engelthaler, David M.
    Erhart, Laura
    Sunenshine, Rebecca H.
    Burwell, Lauren A.
    Park, Benjamin J.
    EMERGING INFECTIOUS DISEASES, 2008, 14 (07) : 1053 - 1059
  • [49] Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
    Rodriguez, George D.
    Warren, Nathan
    Yashayev, Roman
    Chitra, Surya
    Amodio-Groton, Maria
    Wright, Kelly
    FRONTIERS IN MEDICINE, 2023, 10
  • [50] Diabetes and risk of readmission in patients with community-acquired pneumonia
    Jensen, A.
    Dungu, A.
    Olsen, M.
    Ryrso, C.
    Hegelund, M.
    Krogh-Madsen, R.
    Kristensen, P.
    Faurholt-Jepsen, D.
    Lindegaard, B.
    DIABETOLOGIA, 2024, 67 : S478 - S478
12345